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The aim of the present studywas to determine the serum cytokine profile and levels of high sensitivity C-reactive protein (hsCRP) in
patients with uveitis associated with Behc¸et’s disease (BD) and to compare them with those obtained from healthy control subjects.
We determined the serum concentration of interferon-𝛾 (IFN-𝛾), interleukin-1𝛽 (IL-1𝛽), IL-12p70, IL-17A, tumor necrosis factor-𝛼
(TNF-𝛼), and hsCRP in 13 patients with active uveitis associated to BD, 24 inactive BD patients, and 20 controls. In a subgroup
of 10 active patients, a second serum sample was obtained when the disease was inactive. Cytokine profiles and hsCRP levels were
correlatedwith disease activity, severity, complications, and visual outcome. Levels of IFN-𝛾 andTNF-𝛼were significantly increased
in patients with active uveitis associated to BD compared to controls (𝑃 < 0.05). IFN-𝛾, TNF-𝛼, and hsCRPwere significantly higher
during active uveitis associated to BD compared to inactive disease (𝑃 < 0.05). Furthermore, IL-17A was significantly increased
in patients with active BD without pharmacological treatment compared to controls (𝑃 < 0.05). No significant correlations were
found with specific cytokine profiles and disease severity, visual outcome, or complications. In summary, increased serum levels of
IFN-𝛾, TNF-𝛼, IL-17A, and hsCRP were associated with active uveitis associated with BD and might serve as markers of disease
activity.
1. Introduction
Behc¸et’s disease (BD) is a chronic systemic inflammatory dis-
order at the crossroad between autoimmune and autoinflam-
matory syndromes. Major symptoms include oral aphthous
ulcers, genital ulcerations, skin lesions, and ocular lesions [1].
Uveitis, associated with BD, is a sight-threatening condition
that affects 60–80% of BD patients and is characterized in
its more severe form by posterior or panuveitis including
occlusive retinal vasculitis [2]. Although the pathogenesis
of BD remains poorly characterized, it is currently believed
that certain infectious and/or environmental factors are able
to trigger symptomatology in predisposed individuals [2].
Association with Class I MHC (HLA-B∗51) may predispose
to inflammation with engagement of the innate immune
system, and further perpetuation by the adaptive T cell
responses against infectious antigens and/or autoantigens
[1, 3]. The aim of therapeutic strategy in BD is to prevent
the recurrent inflammatory attacks in order to minimize
potential irreversible damage. Systemic corticosteroids (CS)
and immunosuppressive (IS) drugs are the first line of
treatment for severe manifestations of BD [4, 5] but often
do not result in stable remission and a subgroup of patients
keep on suffering flare-ups despite conventional therapy [6].
In these cases, novel biologic responsemodifier (BRM) drugs,
particularly TNF-𝛼 antagonists, have emerged as a valid
option resulting in substantial improvement of long-term
visual prognosis and patients’ quality of life [7].
The current hypothesis for the pathogenesis of BD states
that genetic factors induce a general hyperactivity of the
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immune system and bacterial or viral infection stimulates the
expression of heat shock proteins (HSP) and MICA (MHC
Class I chain-related molecules A). This induces the upreg-
ulation of adhesion molecules in the endothelium (ICAM-
1 and VCAM-1), activation of coagulation, and stimulation
of T cells by secreting IL-6, IL-8, and MCP-1 among others,
continuing elevation of the cytokine production eventually
leading to tissue damage and vasculitis (reviewed in [8]).
Previous studies suggested that BD pathogenesis is predom-
inated by a T helper (Th)1 and Th17 immune response [9–
13] as increased levels of IFN-𝛾, IL-12, and TNF-𝛼 have
been found in patients with BD [10]. Active BD was also
shown to be characterized by increased levels of IL-17A
[11–13]. Furthermore, genetic studies including genome-wide
association studies, identified IL23R-IL12RB2 and IL10 as BD
susceptibility loci [14, 15]. Therefore, Th1/Th17-type immune
responses may play a critical role in BD. However, it is
unclear whether Th1/Th17-related cytokines could serve as
biomarkers of disease activity and the effect of both standard
andnovel therapies on the circulating levels of these cytokines
in BD patients is unknown. Moreover, it is also ill-defined
whether uveitis associatedwith BD is characterized by altered
levels of acute phase reactants such as high-sensitivity (hs)
C-reactive protein (CRP) that may eventually exacerbate the
inflammatory burst further modifying serum inflammatory
cytokine levels.
In the present study,we used amultiplex assay to study the
profile of 5 cytokines and hsCRP in serum samples obtained
from patients with active and inactive BD-associated uveitis
and an age-matched healthy control group. In a subset of
patients, the cytokine profile was analyzed longitudinally
during active and inactive stages of the disease. Additionally,
cytokine profiles were correlatedwith visual outcome, disease
severity, and ocular complications.
2. Materials and Methods
2.1. Subjects. Patients were recruited from the Ophthal-
mology Department, Hospital Clinic of Barcelona (Spain),
between January 2011 and July 2013. Thirty-seven patients
aged 22–71 years (mean age: 40.6 ± 10.8) with uveitis
associated with BD were invited to participate in the study.
Twenty-two patients were male and 15 were female. Thirty-
two patients were Caucasians and 5 were from North of
Africa.
Inclusion criteria were patients diagnosed with BD ful-
filling the diagnostic criteria of the International Study
Group [16] who presented with intraocular inflammation.
The diagnosis of active disease followed the clinical criteria
based on inflammatory cell reaction in the anterior chamber
or vitreous > 0.5+ as per Standardization of Uveitis Nomen-
clature (SUN) and National Eye Institute (NEI) grading
system [17, 18]. Active retinal lesions and retinal vasculitis
were evaluated by indirect ophthalmoscopy, fundus aut-
ofluorescence, and/or fundus fluorescein angiography. Any
mentioned inflammatory sign (i.e., anterior chamber cell
> 0.5+, vitreous cells > 0.5+, active retinal vasculitis, or
active chorioretinal lesions) was enough to be eligible. Ocular
complications included macular edema; tractional, serous,
or rhegmatogenous retinal detachment; retinal tear; retinal
neovascularization; epiretinal membrane; persistent vitreous
opacities; vitreous hemorrhage; and optic atrophy. BD was
considered severe when it included any of the mentioned
complications.
Visual acuity was measured with Snellen charts and was
converted to logarithm of the minimum angle of resolution
(log-MAR) values for statistical analysis. Table 1 summarizes
different features of patients and controls. Immunomodu-
latory treatments that patients were receiving (i.e., CS, IS,
and/or BRM) were also gathered.
For comparison, 20 age-matched (mean age: 40.1 years)
and gender-matched (10 women and 10men) healthy subjects
(by clinical anamnesis, ocular examination, and complete
blood analysis), with no evidence of active ocular disease,
who were waiting for unrelated ophthalmic surgery (cataract,
eyelid benign lesions, etc.), were recruited as a control group.
All patients and controls provided informed consent
and the research followed the tenets of the Declaration
of Helsinki. The Hospital Clinic of Barcelona Institutional
Review Board (IRB) approved this study according to local
and national IRB guidelines.
Blood was collected aseptically just after ophthalmologi-
cal evaluation and serum was prepared and stored at −70∘C
until further cytokine analysis. A total of 13 samples were
obtained from patients with active uveitis and 24 samples
were collected from patients with inactive disease. In a subset
of 10 patients, the cytokine profilewas analyzed longitudinally
during active and inactive stages of the disease during amean
follow-up of 7.2 ± 1.1months.
2.2. Serum Cytokine Determination. The Luminex platform
(Millipore’s MILLIPLEX Human Cytokine/Chemokine kit)
was used to measure serum cytokine levels as recommended
by the manufacturer. Five immunemediators associated with
Th1 andTh17 responses (IFN-𝛾, IL-12p70, IL-17A, IL-1𝛽, and
TNF-𝛼) were determined.These cytokineswere chosen based
on the results of a preliminary study (data not shown) where
10 cytokines were analyzed (IFN-𝛾, IL-1𝛽, IL-2, IL-4, IL-6,
IL-8, IL-10, IL-12(p70), IL-17A, and TNF-𝛼). The cytokine
and chemokine assay plate layout consisted of 7 standards
in duplicate (3.2–2,000 pg/mL), 1 blank well (for background
fluorescence subtraction), 2 internal quality control samples
in duplicate, and 25 𝜇L duplicates of each serum sample.
2.3. Determination of Levels of C-Reactive Protein. Levels of
hsCRP in serum samples were determined by CRP high sen-
sitivity ELISA (hsCRP, IBL International GMBH) following
the manufacturer’s instructions.
2.4. Statistical Analysis. Nonparametric analysis was per-
formed using the Mann-Whitney test for comparison of
unpaired data from two groups and Wilcoxon test for com-
parison of paired data. Differences among the three groups
were evaluated using the Kruskal-Wallis test. Spearman’s cor-
relation analysis was carried out to determine the association
of serum cytokine levels with clinical parameters. Statistical
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Table 1: Clinical characteristics of BD patients and normal controls.
Parameters Normal controls (𝑛 = 20) Active BD patients (𝑛 = 13) Inactive BD patients (𝑛 = 24)
Age (years) 40,1 ± 4,7 31,7 ± 6,8 44,9 ± 9,7
Female/male (𝑛) 10/10 6/7 9/15
Anterior uveitis NA 0/13 4/24
Posterior uveitis NA 5/13 12/24
Panuveitis NA 8/13 8/24
Cells in anterior chamber NA 8/13 0/24
Vitreous cells NA 13/13 2/24
Retinal vasculitis NA 10/13 0/24
Oral ulcers∗ NA 11/13 2/24
Genital organ ulcers∗ NA 9/13 1/24
Erythema nodosum∗ NA 4/13 0/24
Arthritis∗ NA 2/13 0/24
Visual acuity (logMAR) ND 0,36 ± 0,30 0,45 ± 0,73
Data are shown as mean ± SD or absolute numbers.
∗Extraocular lesions observed at the time of blood sampling are shown in this table. Patients whose extraocular lesions were negative may have experienced
these symptoms during an earlier phase of the disease.
BD: Behc¸et’s disease; NA: not applicable; ND: not determined.
significance was set at 𝑃 < 0.05. All calculations were
performed using SPSS Version 18.0 (SPSS, IBM Corporation,
New York).
3. Results
Thirty-seven patients (22 male and 15 female) with uveitis
associated with BD were included in the study. When serum
sample was obtained, patients with active uveitis associated
with BD were receiving the following therapies: 3/13 patients
were not receiving any immunomodulatory treatment (naı¨ve
subjects with first episode of uveitis attack), 7/13 were treated
with BRM (TNF-𝛼 antagonists), 2/13 were receiving CS, and
1/13 was receiving conventional IS therapy. With regard to
the inactive patients group, 13/24 were not receiving any
immunomodulatory treatment due to long-standing remis-
sion, whereas 2 patients were under low-dose CS, 8 patients
were receiving BRM (TNF-𝛼 antagonists), and one patient
was on IS therapy.
Firstly, we analyzed differences in the serum cytokine
profile among patients with active disease, inactive disease,
and healthy subjects. For this purpose the cytokine levels of
13 patients with active ocular BD, 24 different patients with
inactive BD, and 20 controls were determined. Figure 1 shows
IFN-𝛾, IL-12p70, IL-17A, IL-1𝛽, and TNF-𝛼 serum cytokine
levels from each group. Active patients showed the highest
levels of IFN-𝛾, IL-17A, IL-1𝛽, and TNF-𝛼, whereas the
control group had the lowest levels of these cytokines. IFN-𝛾
and TNF-𝛼 levels were significantly higher in active patients
compared to control subjects (Figures 1(a) and 1(e);𝑃 < 0.05).
In fact, IFN-𝛾 correlated well with IL-17A (Spearman’s rho
𝑟 = 0.833; 𝑃 < 0.01) and with TNF-𝛼 (𝑟 = 0.855; 𝑃 < 0.01)
in active patients. TNF-𝛼 also correlated well with IL-17A
(𝑟 = 0.663;𝑃 < 0.05). Patientswith active disease also showed
significantly higher levels of hsCRP compared to inactive
patients (5.91 ± 1.65mg/L active versus 2.19 ± 0.53mg/L
inactive; 𝑃 = 0.029).
In a subgroup of 10 patients, serum sampleswere obtained
during both active and inactive phases of the disease and, as
shown in Figure 2, IFN-𝛾 and TNF-𝛼 levels were significantly
higher during the active phase compared to the inactive
period.
Interestingly, as shown in Figure 3, when considering
only those samples from patients without any pharmacologi-
cal treatment (𝑛 = 3 active and 𝑛 = 13 inactive), IL-17A levels
were also significantly higher in active patients compared
to healthy subjects (Figure 3(b), 𝑃 < 0.05). In addition,
untreated inactive patients also showed significantly higher
levels of TNF-𝛼 compared to healthy subjects (Figure 3(c),
𝑃 < 0.05).
We then analyzed the effect of pharmacological treatment
on the circulating levels of the different cytokines. Thus,
serum cytokine levels in active and inactive patients were
compared between patients with or without treatment. As
observed in Figure 4, IFN-𝛾, IL-17A, and TNF-𝛼 levels were
higher in patients without treatment, although only TNF-
𝛼 levels in active patients with no treatment were statisti-
cally different from those of active patients with treatment
(Figure 4(c)).However, wewere unable to observe differences
in any of the cytokines among the different treatments (data
not shown).
Finally, none of the analyzed cytokines correlated with
visual acuity or disease severity in neither active nor inactive
BDpatients and there were no significant differences between
cytokine or hsCRP levels of patients with occlusive vasculitis
(𝑛 = 5) and those without complications (data not shown).
4. Discussion
Behc¸et’s disease (BD) is a chronic multisystemic inflamma-
tory disease, where autoimmunity seems to play a crucial
role [19, 20]. Ocular involvement affects around 70% of BD
patients [21] and is characterized by relapsing nongranulo-
matous uveitis involving both the anterior and the posterior































































































Figure 1: Cytokine profile and hsCRP levels of serum samples of patients with active BD (𝑁 = 13), inactive ocular BD (𝑁 = 24), and
control subjects (𝑁 = 20). Results are expressed as mean values of cytokine levels (pg/mL) ± SEM. Statistical analysis was performed by
Kruskal-Wallis test (∗𝑃 < 0.05 versus control; ∗∗𝑃 < 0.05 versus control and inactive).
segments of the eye. These ocular lesions are often sight-
threatening, requiring prompt and aggressive treatment to
preserve vision [22]. Although several reports have suggested
involvement ofTh1 andTh17 immune responses in BD [9, 10],
it is still unclear whetherTh1- andTh17-related cytokinesmay
serve as markers of disease activity, severity, and/or visual
outcome. In the present study we aimed to study the serum
cytokine profile and hsCRP levels in patients with uveitis





























































































Figure 2: Levels of IFN-𝛾, IL-12p70, IL-17A, IL-1𝛽, and TNF-𝛼 (pg/mL) ± SEM in the serum of patients with uveitis associated with BD
during the active and inactive stages (𝑁 = 10). Statistical analysis was conducted using the Wilcoxon test (∗𝑃 < 0.05).
























































Figure 3: Circulating levels of IFN-𝛾, IL-17A, and TNF-𝛼 in patients
with active BD (𝑁 = 3) and inactive BD (𝑁 = 13) without treatment
and control subjects (𝑁 = 20). Results are expressed as mean values
of cytokine levels (pg/mL) ± SEM. Statistical analysis was performed
by Kruskal-Wallis test (∗𝑃 < 0.05).
associated with BD and its relationship with visual outcome
and disease severity. We showed that IFN-𝛾, IL-17A, TNF-𝛼,
and hsCRP are increased in active uveitis associated with BD.
We observed that BD patients with active uveitis showed
significantly higher levels of IFN-𝛾 and TNF-𝛼 compared
to healthy subjects. These results are in agreement with
previously published observations that reported increased
levels of IFN-𝛾 and TNF-𝛼 in active BD without treatment,
thus supporting aTh1 immune response [9, 10]. Interestingly,
we observed these effects not only in patients without any
treatment but also in those undergoing pharmacological
treatment. Moreover, the analysis of the cytokine profile in
the subgroup of patients to whom we obtained serum during
both active and inactive stages also revealed that IFN-𝛾 and
TNF-𝛼 significantly increased during the active stage of the
disease. Similarly, IL-17Awas increased in patientswith active
uveitis compared to healthy controls. However, this increase
was statistically significant only in those patients without
treatment. These observations are in agreement with other
groups who found increased levels of circulating IL-17A in
patients with active BD compared to healthy subjects [11, 12],
supporting the involvement of Th17 response in BD. We
observed that IFN-𝛾 correlated well with TNF-𝛼 and IL-17A
in patients with active BD. Additionally, TNF-𝛼 also corre-
lated well with IL-17A in these patients. These observations
support the idea that BD is mediated simultaneously by both
Th1 and Th17 responses. On the other hand, although IL-1𝛽
and IL-12 seemed to be increased in active BD, the difference
did not reach statistical significance and none of the analyzed
mediators correlated with visual outcome or disease severity.
Similarly, we were unable to detect differences in the cytokine
profile of BD patients with occlusive vasculitis and in those
without.
In the present work we also observed significantly higher
levels of circulating hsCRP in patients with active uveitis
associated with BD compared to inactive patients. CRP is the
prototypical acute phase reactant and an active regulator of
the innate immune system. It is considered to be a serum
biomarker for chronic inflammation [23]. Indeed, CRP was
significantly higher in active patients compared not only to
healthy subjects but also to inactive patients. Among the
many functions ascribed to CRP are activation of the classical
complement pathway and inactivation of the alternative
pathway [24]. In plasma, CRP exists as a cyclic pentamer.
However, CRP can undergo dissociation, upon exposure to
acidic or inflammatory conditions, thereby acquiring distinct
functionality [25, 26]. In fact, dissociated monomeric CRP
has been shown to display a proinflammatory phenotype [27–
30]. Therefore, the increased levels of circulating hsCRP in
patients with active uveitis associated with BD could eventu-
ally contribute to the exacerbation of the inflammatory burst
increasing the secretion of Th1- and Th17-proinflammatory
cytokines.
The aim of therapeutic strategy in BD is to prevent recur-
rent inflammatory attacks in order to minimize potential
irreversible damage. As mentioned above, classical treatment
with systemic CS and conventional IS therapies may be
effective in some cases [5]. Nonetheless, there is a subgroup
of patients who keep on suffering flare-ups despite standard
therapy. Thus, in the present work, we also aimed to analyze
the effect of pharmacological treatment on the cytokine
profile of BD. Indeed, we observed that IFN-𝛾, TNF-𝛼, and
IL-17A levels were higher in patients without treatment than
in those with pharmacological treatment in both active and
inactive patients. Nevertheless, we did not observe differences
in the cytokine profile among the different treatments. Our
observations suggest that successful therapies should be
able to prevent recurrent inflammatory attacks by keeping
under check the circulating levels of these proinflammatory
cytokines. However, inactive patients maintained signifi-
cantly higher levels of TNF-𝛼 than controls, thus keeping a
proinflammatory background.
Our cohort of patients with uveitis associated with BD
was very representative as it included patients with different
demographic origins. In fact, we did not observe differences























































Figure 4: Effect of treatment on circulating levels of IFN-𝛾, IL-17A, andTNF-𝛼 (pg/mL)± SEM in patients with active and inactive BD. Results
are expressed as mean values of cytokine levels (pg/mL) ± SEM. Statistical analysis was performed by MannWhitney U-test (∗𝑃 < 0.05).
in the cytokine profile between Caucasian and African
patients (data not shown), which allows us to speculate that
the observed increased levels of IFN-𝛾, TNF-𝛼, and IL-17A
may apply to uveitis associated with BD from any origin.
The main limitation of the present work is the sample size,
specially the group of active patients without treatment as
well as the heterogeneity of treatment modalities. Neverthe-
less, the fact that our results were observed across such a
heterogeneous group also reinforces our findings.
5. Conclusions
In conclusion, our study shows that active BD is associated
with increased serum levels of IFN-𝛾, TNF-𝛼, IL-17A, and
hsCRP compared to inactive disease or healthy controls.
Although further research is warranted to elucidate the
role of these mediators in BD, serum cytokine profiling
may contribute to the understanding of the physiopathology
processes underlying retinal damage in BD and provide tools
for new biomarkers and/or personalized treatment targets.
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